Jeremy Skillington of Poolbeg Pharma discusses their consortium award of €2.3m in non-dilutive grant funding
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington CEO of discusses how 'EncOVac', a consortium led by Poolbeg, has been awarded €2.3m in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government's Disruptive Technologies Innovation Fund.
Highlights
Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the development of an oral vaccine candidate to a Phase I ready state. The resulting technology will serve as a platform for additional oral vaccine candidates for a wide range of pathogens, initially targeting bacterial infections. Poolbeg is proud to play a role in the development of the next generation of vaccine technologies that can protect the world from infectious diseases.
To read the full RNS click here
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.